Multiple studies confirmed that LMT-28 reduced gp130 in the IL-6 pathway, phosphorylation of STAT3 with ERK to block signaling, and inhibited of Th17 differentiation, thereby improving arthritis symptoms in CIA, and had a combined effect with metformin (264–266). This evidence concerns the gene IL6 and arthritic joint disease.